FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2547679356> ?p ?o ?g. }

• W2547679356 abstract "Abstract The use of subcutaneous (SC) low molecular weight heparin (LMWH), such as enoxaparin, in pediatric patients for treatment or prevention of thromboembolism is now considered standard practice; however, SC administration is often difficult in special populations such as premature neonates, children with minimal subcutaneous tissue, and critically ill children with severe edema. Impaired SC absorption may lead to difficulty achieving adequate anticoagulation, as measured by anti-Xa levels 4 to 6 hr after the second or third dose. Intravenous (IV) administration of enoxaparin has, therefore, been employed in our intensive care unit (ICU) in an attempt to achieve adequate anticoagulation. However, the published experience of IV dosing and its monitoring consists of one brief manuscript and one abstract describing one preterm infant each. Therefore, we retrospectively evaluated dosing, monitoring, and clinical outcomes of pediatric patients receiving IV enoxaparin in our ICU between April 1, 2005 and March 31, 2006. Seven patients, all with congenital heart defects, were identified using hospital pharmacy records. Five were switched to IV enoxaparin after having difficulty achieving therapeutic anti-Xa levels with SC administration, primarily due to marked edema. Two others were empirically started on IV enoxaparin. Five children were treated with enoxaparin for thrombosis and 2 were treated prophylactically. Median age at the initiation of IV enoxaparin was 4 mo (range, 18 d – 3 yr). Dosing of the enoxaparin was every 8 hr for the 5 children under 1 yr of age and every 12 hr for the 2 children over 1 yr of age. Of the total 64 anti-Xa levels obtained, 19 monitored the 12 hr dosing schedule and 45 the 8 hr schedule. In order to evaluate the anti-Xa levels drawn following different doses (mg/kg) and dosing regimens (q8h or q12h) we transformed the data by the following equation: anti-Xa level (IU/ml)/total daily dose of enoxaparin· kg−1. These transformed values were averaged and grouped by the time of the anti-Xa level after enoxaparin, as follows: Average anti-Xa levels, enoxaparin dose, and transformed levels grouped by time level obtained Time level drawn (hr) Anti-Xa level (U/ml) Dose (mg/kg/day) Anti-Xa/dose 0–1.9 0.68 4.67 0.19 2–3.9 0.46 3.67 0.15 4–5.9 0.77 5.93 0.16 6–8.0 0.13 5.98 0.03 The average enoxaparin dose necessary to achieve the therapeutic target (anti-Xa 0.5–1.0 IU/ml) at 1–2 hr for the 3 children &lt; 1 yr of age was 2.4 mg/kg (± s.d. 0.58) q8h. The average dose to achieve the prophylactic target (anti-Xa 0.3–0.5 IU/ml) at 1–2 hr for the 2 children &lt;1 yr of age was 0.93 mg/kg (± s.d. 0.43) q8h. In the 2 children &gt; 1yr of age, the average dose to achieve the therapeutic target at 1–2 hr was 1.11 mg/kg (± s.d. 0.13) q12h. No serious bleeding complications occurred in any patient. In conclusion, IV enoxaparin dosing appears to exhibit different pharmacodynamics than SC dosing, with higher anti-Xa levels at 1 to 2 hr after administration rather than at 4 to 6 hr. More frequent administration may be indicated as the levels decrease substantially 6 to 8 hr following an IV dose. The average dose needed for therapeutic levels may be higher than with SC administration (especially in the younger child). Future prospective studies should be conducted to determine the pharmacodynamics of IV enoxaparin, its safety and its clinical indications." @default.
• W2547679356 created "2016-11-11" @default.
• W2547679356 creator A5001681960 @default.
• W2547679356 creator A5033695026 @default.
• W2547679356 creator A5072267313 @default.
• W2547679356 date "2006-11-16" @default.
• W2547679356 modified "2023-09-29" @default.
• W2547679356 title "Experience with Intravenous Enoxaparin in Critically Ill Infants and Children." @default.
• W2547679356 doi "https://doi.org/10.1182/blood.v108.11.881.881" @default.
• W2547679356 hasPublicationYear "2006" @default.
• W2547679356 type Work @default.
• W2547679356 sameAs 2547679356 @default.
• W2547679356 citedByCount "2" @default.
• W2547679356 crossrefType "journal-article" @default.
• W2547679356 hasAuthorship W2547679356A5001681960 @default.
• W2547679356 hasAuthorship W2547679356A5033695026 @default.
• W2547679356 hasAuthorship W2547679356A5072267313 @default.
• W2547679356 hasConcept C126322002 @default.
• W2547679356 hasConcept C141071460 @default.
• W2547679356 hasConcept C177713679 @default.
• W2547679356 hasConcept C187212893 @default.
• W2547679356 hasConcept C2776376669 @default.
• W2547679356 hasConcept C2776884760 @default.
• W2547679356 hasConcept C2777288759 @default.
• W2547679356 hasConcept C2778825682 @default.
• W2547679356 hasConcept C2780868729 @default.
• W2547679356 hasConcept C42219234 @default.
• W2547679356 hasConcept C71924100 @default.
• W2547679356 hasConceptScore W2547679356C126322002 @default.
• W2547679356 hasConceptScore W2547679356C141071460 @default.
• W2547679356 hasConceptScore W2547679356C177713679 @default.
• W2547679356 hasConceptScore W2547679356C187212893 @default.
• W2547679356 hasConceptScore W2547679356C2776376669 @default.
• W2547679356 hasConceptScore W2547679356C2776884760 @default.
• W2547679356 hasConceptScore W2547679356C2777288759 @default.
• W2547679356 hasConceptScore W2547679356C2778825682 @default.
• W2547679356 hasConceptScore W2547679356C2780868729 @default.
• W2547679356 hasConceptScore W2547679356C42219234 @default.
• W2547679356 hasConceptScore W2547679356C71924100 @default.
• W2547679356 hasLocation W25476793561 @default.
• W2547679356 hasOpenAccess W2547679356 @default.
• W2547679356 hasPrimaryLocation W25476793561 @default.
• W2547679356 hasRelatedWork W1512532008 @default.
• W2547679356 hasRelatedWork W1604196400 @default.
• W2547679356 hasRelatedWork W2070968988 @default.
• W2547679356 hasRelatedWork W2087392466 @default.
• W2547679356 hasRelatedWork W2118015645 @default.
• W2547679356 hasRelatedWork W2124549786 @default.
• W2547679356 hasRelatedWork W2411496450 @default.
• W2547679356 hasRelatedWork W2414995746 @default.
• W2547679356 hasRelatedWork W2772121106 @default.
• W2547679356 hasRelatedWork W3148461121 @default.
• W2547679356 isParatext "false" @default.
• W2547679356 isRetracted "false" @default.
• W2547679356 magId "2547679356" @default.
• W2547679356 workType "article" @default.